Anxiety Disorders

Anxiety disorders are a group of mental disorders in which fear or worry is persistent, excessive, and out of proportion to the actual threat, and in which the resulting distress or avoidance significantly impairs social, occupational, or other areas of functioning. Clinicians distinguish them from ordinary anxiety by their intensity, duration, and impact, and from fear, which is a response to a present or imminent threat, whereas anxiety is largely anticipatory. They are among the most common psychiatric conditions. Prevalence estimates vary with the time frame used, from roughly one in five adults in the United States over a single year to about one third of people at some point in their lives, and they are frequently underdiagnosed. Anxiety disorders are associated with depression, substance use, sleep problems, reduced quality of life, and, in some cases, suicidal thoughts and attempts.

This entry explains how the disorders are defined and classified in the DSM-5-TR and ICD systems, and why some related conditions such as obsessive-compulsive disorder and post-traumatic stress disorder are now grouped separately. It then describes the main types, including generalized anxiety disorder, panic disorder and agoraphobia, social anxiety disorder, specific phobias, and childhood-onset separation anxiety and selective mutism. The entry also reviews epidemiology and course, the biological, psychological, and environmental factors implicated in their development, the diagnostic process and its differential diagnosis, and the main psychological and pharmacological treatments. It closes with the global treatment gap and with open questions in research and classification.

Defining Anxiety Disorders and Their Core Features

Anxiety disorders are a family of conditions in which excessive fear, anxiety, and related behavioral disturbances cause clinically significant distress or impairment. The DSM-5 and its text revision, DSM-5-TR, use this shared core to group disorders that otherwise differ in their triggers and in their typical age of onset (see diagnosis for how such criteria are applied). Excessive fear and anxiety are not a single symptom. They are a pattern that includes thoughts, bodily sensations, and behavior, and the disorders differ mainly in which of these dominate and what situations set them off.

Fear and anxiety

The DSM-5-TR separates the two states by their time frame. Fear is an emotional response to a threat that is real or perceived as imminent. Anxiety is oriented toward a threat that has not yet arrived. The two overlap, but they tend to show different profiles. Fear is more often linked to a surge of autonomic arousal, thoughts of immediate danger, and escape. Anxiety is more often linked to muscle tension, vigilance, and cautious or avoidant behavior aimed at future danger. This distinction is more than a matter of definition. It shapes which treatments target which processes, and it helps explain why some disorders, such as panic disorder, feature sudden bursts of fear, while others, such as generalized anxiety disorder, feature prolonged worry.

Symptoms

Anxiety disorders involve both bodily and cognitive symptoms. Physical features commonly include a racing heart, sweating, trembling, shortness of breath, chest discomfort, and dizziness. Cognitive and behavioral features include a sense of being keyed up or on edge, restlessness, easy fatigue, difficulty concentrating or a mind that goes blank, irritability, muscle tension, and disturbed sleep. The same symptoms appear across several diagnoses, so the pattern and context matter more than any single item. In generalized anxiety disorder, for example, the DSM-5-TR requires at least three of six such symptoms in adults, with only one required in children. Symptoms are therefore not diagnostic on their own. Many people experience some of them during ordinary stress without meeting any disorder.

Distress, impairment, and the threshold for disorder

Anxiety and fear are normal and adaptive. They help people respond to real dangers, and most people feel them at some point without any need for clinical attention. What separates a disorder from ordinary experience is a combination of features. The fear or worry must be out of proportion to the actual likelihood or impact of the feared event. It must be hard to control. It must persist over time, and it must cause clinically significant distress or impair functioning in social, occupational, or other important areas of life. For generalized anxiety disorder, the DSM-5-TR sets the duration at more days than not for at least six months. This duration requirement filters out situational anxiety linked to a specific stressor, such as a job loss or a medical diagnosis, which usually eases as circumstances change. Mild, transient anxiety before an exam or a flight therefore does not meet the definition, even though it is uncomfortable. The question is whether the anxiety is persistent, disproportionate, and disruptive, rather than whether it is present at all.

Avoidance as a maintaining factor

Avoidance is one of the most consistent features across anxiety disorders, and it is central to how they persist. Avoiding a feared object, place, or social situation reduces distress in the short term, which reinforces the avoidance. Over time, however, avoidance prevents the person from learning that the feared outcome may not occur or that they could cope with it. It also narrows daily life, limiting work, travel, relationships, and routines. The same mechanism appears in disorders with different content, including panic-related agoraphobia, social anxiety, and specific phobias. Because avoidance maintains the disorder, many treatments, especially exposure-based approaches, deliberately target it. Later sections of this entry discuss the individual disorders, their prevalence, and their treatment in more detail.

Classification and Diagnostic Systems

DSM-5 and DSM-5-TR

The DSM-5 anxiety chapter is sequenced by developmental timing rather than by theme. The chapter is arranged from earlier onset to later onset, as is generally the case across DSM-5. In the DSM-5-TR, separation anxiety disorder and selective mutism tend to arise during childhood, whereas the other disorders listed above generally develop in adulthood. The sequence runs through specific phobia, social anxiety disorder, panic disorder, agoraphobia and generalized anxiety disorder, and then closes with anxiety induced by substances or medications, anxiety attributable to another medical condition, and residual "other specified" and "unspecified" categories.

What moved out of the anxiety chapter, and why

The older framework was broader than the current one. DSM-IV-TR included 12 anxiety disorder categories, grouping disorders such as generalized anxiety disorder and specific phobias together with OCD and PTSD. DSM-5 separated these into distinct groupings. The major change was to move the obsessive-compulsive and related disorders and the trauma-related and stressor-related disorders into separate chapters. The stated aim was to better reflect common diagnostic validators, meaning features that clinicians and researchers could use to define each group. Conditions that often present with prominent anxiety, such as acute stress disorder, adjustment disorders, and posttraumatic stress disorder (PTSD), are placed in the trauma chapter, because they are deemed to arise out of traumatic or stressful experiences.

The childhood-related disorders were also re-sorted. In DSM-IV, separation anxiety disorder and selective mutism sat among childhood disorders, and separation anxiety required onset before age 18. DSM-5 classifies both as anxiety disorders, unlike their previous placement, and it dropped the age-of-onset requirement. The change followed evidence that a substantial portion of adults report first onset in adulthood, which the earlier criterion did not reflect.

ICD-11 and the differences from DSM

The World Health Organization's ICD-11 was approved by the World Health Assembly in May 2019. Its anxiety group includes disorders in which anxiety or fear are the primary clinical feature, and separation anxiety disorder and selective mutism have been moved from the childhood disorders section to the anxiety category. The two systems were deliberately harmonized to avoid disjunctions in health statistics internationally, and harmonization is most evident at the meta-structure level of disorder groupings.

Detailed differences remain. ICD-11 has a looser threshold for generalized anxiety, requiring symptoms for "at least several months" rather than DSM-5's six months. It also omits subcategorizations and a precise minimum number of required symptoms. Panic disorder and agoraphobia can now be given separately and comorbidly. ICD-11 places hypochondriasis in a chapter on obsessive-compulsive and related disorders, while mixed anxiety and depressive presentations are classified in the group "affective disorders". These choices reflect the importance placed on global applicability and clinical utility, particularly in low-resource settings, a consideration relevant to the WHO role in international reporting.

From a single "neurotic" construct to a multi-category framework

Before 1980, anxiety was understood largely through the concept of neurosis. DSM-II stated that anxiety was the chief characteristic of "neuroses", and the broad category of anxiety neurosis covered both panic and generalized symptoms. The shift came with DSM-III. The term "neurosis" was removed from the DSM-III altogether. Generalized anxiety disorder (GAD) appeared as a diagnostic category in the third edition of the DSM (DSM-III) in 1980, when anxiety neurosis was split into GAD and panic disorder. The separation was supported in part by pharmacological evidence: the distinct responses these two disorders had to imipramine therapy was one reason to distinguish between the two.

The older picture also had a treatment dimension. Anxiety was treated as one broad condition, and researchers and clinicians have been searching for effective, safe agents to treat anxiety symptoms and disorders for over a century. Sedative drugs such as barbiturates and benzodiazepines were central to that search, the so-called anxiolytics. Once disorders were separated into distinct categories, clinicians could ask whether each condition needed a different approach, which is part of why the modern framework matters for pharmacological and psychological treatment decisions alike.

Generalized Anxiety Disorder

Generalized anxiety disorder (GAD) is defined by worry that is hard to switch off and that attaches to many everyday matters at once, such as job performance, money, health and family, rather than to one object or setting. This worry spans several areas of life, happens more days than not for at least six months, and is not tied to specific situations. Worry is what sets GAD apart from the other anxiety disorders, although worry also appears in other conditions.

Diagnostic Criteria

Under DSM-5-TR, a clinician looks for apprehension about several activities that recurs on more days than not for at least six months, with work and school performance given as examples. Restraining these thoughts is a struggle for the affected person, and worry alone is not sufficient. At least three of six accompanying features must also be present, including restlessness, easy fatigue, poor concentration, irritability, muscle tension, and disturbed sleep, and the symptoms must cause meaningful distress or impair social or occupational functioning. Other causes are excluded. Substance use or a general medical condition such as an overactive thyroid must not account for the anxiety, and another psychiatric disorder must not explain it better. Although DSM-5 was revised, the final criteria remained largely consistent with DSM-IV.

Distinguishing GAD from Normal Worry

Ordinary worry is a normal part of life, and the diagnostic criteria exist to separate a clinically significant condition from that everyday experience. Clinicians weigh whether the apprehension outstrips what the real odds or stakes would justify. The duration requirement does much of the work: the six-month threshold filters out situational anxiety tied to a particular event. Impact on daily functioning is the third consideration, since the criteria look at how long the worry lasts and how it affects daily life.

Prevalence and Demographic Patterns

Estimates depend heavily on method. In general-population surveys, lifetime prevalence has varied considerably, from about 6.6% in a Durham, North Carolina sample to 21.7% in Iceland. A 2025 analysis of US insurance claims reported a prevalence of 10.3% for 2021–2023, a figure derived from a different data source and therefore not directly comparable with survey results. In that analysis, the disorder affected 3.4% of women compared to 1.9% of men. This ratio of roughly 1.8 is consistent with the twofold female excess commonly reported. A meta-analysis of older adults found that lifetime prevalence was significantly higher in women than men for generalized anxiety disorder (lifetime OR = 1.96).

Older Adults

GAD is often described as the most common anxiety disorder in later life. One review gives prevalence rates in older adults of between 2.8% and 7.3%. However, the picture is not uniform. In a European cross-sectional survey of people aged 65 to 84, agoraphobia was the most frequent disorder (4.9%), followed by panic disorder (3.8%), animal phobia (3.5%), and general anxiety disorder (3.1%), so GAD ranked fourth in that sample. Late-life cases also have distinct origins: some were late-onset cases of GAD triggered by recent adverse life events and by chronic physical or mental (depression) health disorders.

Comorbidity

GAD often coexists with health conditions like depression, other anxiety disorders, and substance use disorders, and these additional conditions can complicate diagnosis and treatment due to symptom overlap. Estimates of lifetime co-occurrence with depression range widely; one commonly cited figure is that comorbid depression (lifetime prevalence) is seen in 43% of those with general anxiety disorder. The reverse direction is also common: in one Chinese outpatient sample, 667 patients were diagnosed with major depressive disorder, of whom 71.7% had GAD.

Alcohol is a frequent partner. For patients with generalized anxiety disorder, the lifetime prevalence of comorbid alcohol abuse and dependence is 30% to 35%. A national US survey analysis found that controlling for demographics and comorbidities, lifetime GAD was positively associated with lifetime Alcohol and Cannabis Use Disorder. Panic disorder also overlaps with GAD, particularly through shared somatic symptoms such as restlessness and sleep disturbance, although the overlap makes it harder to assign a single primary diagnosis.

Panic Disorder and Agoraphobia

Panic attacks and panic disorder

A panic attack is a sudden onset of intense fear or discomfort that is discrete and brief rather than a gradual build-up. The diagnostic definition requires at least 4 of 13 listed physical and cognitive symptoms to be present during the episode. The episodes are frightening but are not dangerous in themselves, even though people often mistake them for a heart attack or another life-threatening event.

Panic disorder is a different construct. It refers to repeated panic attacks, typically accompanied by fears about future attacks or by changes in behavior to avoid situations that might bring on an attack. The recurrent worry, rather than the attacks alone, is what defines the condition. Many patients also worry that they have a dangerous heart, lung, or neurologic disorder and repeatedly visit their primary care clinician or an emergency department.

Clinicians distinguish expected from unexpected attacks. Unexpected panic attacks are those that occur spontaneously, without any apparent trigger. Examples include attacks that begin during rest or on waking from sleep. Expected attacks occur when a cue is present, such as entering a feared setting. The classification is made by the clinician, and approximately one-half of individuals with panic disorder have both expected and unexpected attacks, so the presence of expected attacks does not rule out the diagnosis. The distinction itself is contested. Prospective monitoring found that the state measured before unexpected attacks did not differ from the ongoing non-panic state, and some researchers suggest that whether an attack is labelled expected or unexpected may depend on a person's sensitivity to bodily change rather than marking a fundamental nosological category.

Prevalence estimates vary with the time frame used. In a large US survey, over 28% of US adults had experienced at least one panic attack in their lifetime, with over 11% having had one in the past year. Panic disorder itself has been estimated at about 5% lifetime, a figure cited in genetic research on the condition.

Agoraphobia

DSM-5 created agoraphobia as a separate diagnosis, whereas in the previous version, DSM-IV, panic disorder could be diagnosed as "panic disorder with agoraphobia". Under current criteria, the core feature is marked fear or anxiety about at least two of five situations: public transportation, open spaces, enclosed places, crowds or standing in line, and being outside the home alone. The fear must be tied to thoughts that escape might be difficult, or help might not be available in the event of developing panic-like symptoms or other incapacitating or embarrassing symptoms. The same situations nearly always trigger fear or anxiety, and patients actively avoid them and/or require the presence of a companion. The pattern is usually persistent, lasting at least six months. Because the feared outcome is often a panic attack, the two conditions overlap substantially, but the agoraphobia diagnosis is made irrespective of the presence of panic disorder.

Avoidance and its consequences

Avoidance is the central maintaining mechanism. Early avoidance responses to anticipatory anxiety, such as refusing to enter a shop without a companion, can become a defining feature of the disorder. Patterns of agoraphobic avoidance may range from just a few situations, such as driving and crowds, to multiple situations. In severe cases, the individual becomes housebound, rarely leaving the house and, if so, only when accompanied. Such restrictions can change daily routines and impair one's ability to perform routine tasks, work, socialize, and maintain relationships.

Sex differences and onset

Panic disorder is clearly more common in women. In the US National Comorbidity Survey, a DSM-III-R diagnosis of lifetime panic disorder was about 2.5 times more common in female than in male respondents. The gap widens with age: among respondents aged 15 to 24, the rate of panic disorder was 2.5%, compared with 1.3% for male respondents, and among those aged 35 to 44 the female rate was 2.1% against 0.6% for men. Other analyses report a ratio closer to 2:1 for lifetime panic disorder, and women are more likely to have panic disorder with agoraphobia. Among women with panic disorder in one follow-up cohort, recurrence of panic symptoms was higher (82%) than in men (51%).

Biological and developmental explanations remain under investigation. Respiratory symptoms during attacks are more frequent in women, who may be more sensitive to carbon dioxide than men. Among peripubertal girls, panic attack rates rose with each stage of pubertal development. Onset of panic disorder is most typical in early adulthood; in one NCS-based analysis, average age at onset was in the early twenties.

Social Anxiety Disorder and Specific Phobias

Social anxiety disorder

Social anxiety disorder centres on a strong fear of being judged, embarrassed or humiliated in situations involving other people or performance before an audience. Public speaking is the most commonly reported social fear, but the same fear often attaches to meeting unfamiliar people, eating or writing in front of others, or being observed at work. DSM-5 separates two presentations. In the generalized form, fear and avoidance extend across a wide range of social settings. In the performance-only form, distress is confined to one or a few specific situations, such as giving a presentation or using a public restroom.

Prevalence estimates vary with the survey instrument, the sample and the time frame. A U.S. survey figure of about 13% is often cited for lifetime prevalence, while one review gives a range of roughly 7% to 12%. Twin research indicates a heritable basis for social anxiety, and the trait appears to share genetic influences with neuroticism and extraversion. Heritability estimates are inconsistent: a systematic review found values from 13% to 76% across studies, reflecting differences in measurement and statistical models, and one longitudinal twin study attributed about 59% of variance to additive genetic effects. Genome-wide studies have so far not identified robust individual risk variants. Their overall contribution is modest, with SNP-based heritability estimates of around 12%.

The disorder is linked to impairment in education, social life and work. Among the anxiety disorders, social anxiety has been reported as the one most predictive of not progressing from high school to college, which suggests that early onset can shape educational paths. In occupational settings, about 20% of people with the disorder have reported turning down a job offer or promotion because of social fears. In a primary care sample, patients with social anxiety disorder were more than twice as likely to be unemployed as other patients, and they showed lower educational attainment and reduced income. Avoidance is central to these outcomes: avoiding feared situations prevents people from learning that their anticipated humiliation rarely occurs, which keeps the fear in place.

Specific phobias

A specific phobia is a persistent, excessive fear of a clearly identifiable object or situation, one that is out of proportion to the actual danger and usually prompts avoidance. Conventional subtypes include animals, the natural environment (heights, storms, water), blood-injection-injury, situational triggers (such as flying, enclosed spaces or dental care) and other fears, including fear of vomiting. Most people with one phobia have several feared stimuli; in one review the average was about three.

Estimates of lifetime prevalence range from about 3% to 15% across countries. In a 25-country adult survey, lifetime prevalence was 7.4% and 12-month prevalence was 5.5%, and a U.S. survey reported a lifetime figure of 9.4%. Subtype frequencies differ markedly. In a representative sample of young women in Dresden, lifetime prevalence of the whole category was 12.8%, but individual subtypes ranged from 0.2% for vomiting to 5.0% for animals. Fears of heights and animals are generally the most common.

Specific phobias show a consistent sex difference. Across the World Mental Health Surveys, most subtypes were more frequent in women, and the 12-month female-to-male ratio was about 2.3. The imbalance is most pronounced for vomiting phobia, where the female-to-male ratio among adults seeking treatment was about 9 to 1. Onset typically occurs in childhood or early adolescence, and in many cases symptoms have appeared before age 10, with the age of onset varying by subtype. Girls tend to show symptoms at younger ages than boys. Phobias can persist for decades in a substantial minority of cases, and they strongly predict later anxiety, mood and substance-use disorders. Childhood-onset phobias with several subtypes carry particular risk: in a multinational sample, lifetime suicide attempts were reported by about 17% of people with four or more childhood subtypes, compared with about 2% of those without childhood phobia.

Avoidance in specific phobias has practical consequences. Fear of flying can restrict travel and career options, fear of injections or dental procedures can lead people to delay necessary care, and fear of animals or crowded places can narrow school and social routines. Because the developmental course often moves from fear to avoidance and then to diagnosis, early intervention may limit both the phobia itself and the later disorders it tends to precede.

Childhood-Onset Anxiety Disorders

Two anxiety disorders are usually first recognized in childhood: separation anxiety disorder and selective mutism. Both appeared in the DSM-IV chapter for disorders first diagnosed in infancy, childhood, or adolescence, and DSM-5 moved them into the anxiety disorders chapter, a change that reflected the view that their core mechanism is anxious fear rather than a developmental delay.

Separation anxiety disorder

Separation anxiety disorder involves fear or worry about being apart from home or from attachment figures such as parents and caregivers, and that fear is out of step with the child's developmental stage. DSM-5 requires at least three of eight specified symptoms, such as distress when anticipating separation, persistent worry about harm befalling attachment figures, and reluctance to sleep away from home. In children, the symptoms must last at least four weeks; in adults the threshold is typically six months. Prevalence is roughly 4% in children over a six- to twelve-month period, falling to about 1.6% in adolescents in the United States. It is the most common anxiety disorder in children under twelve, and its prevalence declines through adolescence and adulthood. Sex differences depend on the setting: clinical samples show roughly equal rates in boys and girls, whereas community samples show more cases in girls.

Selective mutism

Selective mutism is a consistent failure to speak in specific social situations where speech is expected, most often school, while the child speaks normally at home. Onset is usually before age five, but the condition is frequently not recognized until school entry raises the demand for speech in front of peers and teachers. Prevalence estimates vary widely, from about 0.03% to 1% in older compilations to around 1–2% in more recent reviews; the differences reflect sample type, informant, and diagnostic criteria. A Swedish school-based screening of seven- to fifteen-year-olds found a rate of about 18 per 10,000 for typical cases, and a school-based study in the United States reported a rate of about 0.7%. Girls are somewhat over-represented in many clinical samples, but the sex ratio tends to be closer to parity in community samples. A meta-analysis of 22 studies (N = 837) found that about 80% of children with selective mutism also met criteria for another anxiety disorder, most often social anxiety disorder, which the authors took as evidence that anxiety diagnoses are not fully separable categories. Oppositional symptoms are reported in as many as 30% of affected youth.

DSM-5 refinements

The main change in DSM-5 was the removal of the rule that separation anxiety must begin before age eighteen. Under DSM-IV, adults with separation anxiety symptoms were often assigned to panic disorder, agoraphobia, or generalized anxiety disorder instead. DSM-5 retained the childhood presentation but rewrote symptom descriptions so they apply to adults and older adolescents, and it allowed diagnosis across the lifespan. Critics have noted that the criteria still count each symptom equally, even though some symptoms have better diagnostic value than others, and that the new lifespan framework has not been fully tested in clinical use.

Impairment

Childhood anxiety disorders are not benign. Separation anxiety is associated with marked problems in personal, social, and academic functioning. In a school-based study of selective mutism, affected children were more symptomatic than peers on speech frequency, social anxiety, and other internalizing symptoms. They had improved after six months but remained impaired, which the authors took to argue against waiting for spontaneous remission. Impairment is often most visible in school, where it can affect learning, peer relationships, and participation in class.

Assessment in young people

Assessing children requires information from several sources. Because a child with selective mutism may speak fluently at home, parents' reports alone can miss the problem, and teachers are often the first to notice it. Several factors can complicate diagnosis: parental mental health conditions, a family history of shyness or selective mutism, language or communication difficulties, and autistic features can all overlap with the presenting picture. Children who are silent at school are sometimes described as "just shy" or misdiagnosed as autistic. A systematic review of selective mutism literature found that 38% of published studies with original data did not use any standardized or objective measure of core symptoms, and a psychometric scale for youth anxiety found that its selective mutism items were often assigned to social anxiety. Multi-informant assessment, with structured instruments and information from schools, is therefore central to routine evaluation, and teacher awareness is a practical priority for early identification.

Epidemiology and Course

Prevalence and the choice of time frame

Prevalence estimates depend on whether they describe a single moment, a year, or a whole lifetime. Global figures are mostly modelled rather than counted. The Global Burden of Disease analysis for 2019 estimated that 4.05% of the global population has an anxiety disorder, translating to 301 million people. Later rounds of the same modelling produced higher totals. WHO's current fact sheet reports that in 2023, 470 million people were living with an anxiety disorder including 146 million children and adolescents. Part of this rise reflects updated data and population growth, not necessarily a change in underlying rates. Prevalence is also higher in wealthier settings: the GBD analysis found the prevalence is higher in high-income regions.

Lifetime estimates are larger than point or one-year estimates, because they count everyone who has ever met criteria. A study of US children, adolescents and young adults aged 6 to 25 reported that approximately 19 % experience an anxiety disorder in their lifetime. For US adults, an NIMH survey program from 2001 to 2003 found that 31.1% of U.S. adults reported a lifetime anxiety disorder. Lifetime figures also vary widely between countries, partly because survey instruments, diagnostic thresholds and sampling differ. One comparison cited a lifetime prevalence of 0.1% in Nigeria and 8.6% in Canada, a contrast that the authors attribute at least partly to methodological differences.

Sex differences

Anxiety disorders are more common in women. WHO notes that women are affected more than men, and the pattern appears across both community surveys and clinical samples. The difference is not explained by an earlier onset in women: a meta-analysis of age of onset revealed no difference in the AOO between genders. This suggests that the higher lifetime rates in women arise from differences in risk or persistence rather than from timing of first onset. The explanations for these differences, including hormonal and social factors, are discussed in the causes section.

Age of onset

Most anxiety disorders begin in childhood, adolescence or early adulthood. A large meta-analysis found a mean age of onset for all anxiety disorders of 21.3 years, but the averages mask marked differences between subtypes. Separation anxiety disorder, specific phobia, and social phobia had their mean onset before the age of 15 years, whereas the AOO of agoraphobia, obsessive-compulsive disorder, posttraumatic stress disorder, panic disorder, and generalized anxiety disorder began, on average, between 21.1 and 34.9 years. Earlier Kessler and colleagues' reviews of age of onset similarly found that phobias had a median onset of 7 to 14 years, earlier than other anxiety disorders.

For this reason, the claim that many symptoms appear before age 21 is well supported. Reviews note that onset of anxiety symptomology is most likely to occur before the age of 21, with many specific anxiety disorders developing before age 15. Across all mental disorders, the National Comorbidity Survey Replication found that half of all lifetime cases started by the age of 14 years and three-fourths by the age of 24 years. Because retrospective recall tends to underestimate early onset, and because many people wait years before seeking treatment, the gap between first symptoms and first care is often substantial.

Chronicity, relapse and comorbidity

Anxiety disorders often follow a persistent course. Researchers describe the tendency to relapse for a long time and the disabling nature of these conditions as reasons for concern. When untreated, they often persist and can contribute to the development of other psychiatric disorders. Comorbidity is common. Anxiety frequently co-occurs with depression, and the two conditions can overlap in ways that make each harder to recognise. Physical symptoms also accompany many anxiety disorders, with palpitations, dizziness and insomnia reported as frequent features.

Underdiagnosis and suicide risk

Many people with anxiety disorders are not identified or treated. Records from one nationwide Swedish review showed that suicidal thoughts were noted by a psychiatrist in nearly 30 % of all individuals with anxiety symptoms, compared to 7 % in those without such symptoms. The same review pointed to little documentation related to mental health, which may indicate underdiagnosis as well as other explanations.

Anxiety is also linked to suicidal thoughts and behaviour, although the strength of the association is debated. A recent meta-analysis reported that people with an anxiety disorder are nearly 5 times more likely to attempt suicide than are people without an anxiety disorder. A separate meta-analysis, which treated anxiety as a broader dimension, described it as a weak predictor of suicidality. Population-based longitudinal data support an independent association: a pre-existing anxiety disorder was an independent risk factor for later suicidal ideation and attempts, although it is not yet clear whether treating anxiety reduces this risk.

Causes and Risk Factors

No single cause explains anxiety disorders. Most research describes a multifactorial model in which inherited vulnerability, temperament, early experience, and physiological or substance-related factors interact, and each disorder has its own profile of contributors.

Genetic and familial contributions

Family aggregation is among the most consistent findings. Twin studies have long compared concordance between identical (monozygotic) and fraternal (dizygotic) twins. An early DSM-III-R study found that for panic disorder and generalized anxiety disorder the monozygotic-to-dizygotic concordance ratio exceeded 2:1, which supported a genetic contribution to both conditions. A meta-analytic estimate places the twin heritability of separate anxiety and depressive disorders at roughly 30–50%, a moderate share of risk. Heritability can be higher for particular dimensions. In a 2025 longitudinal study of 6,429 twin pairs followed from age 23 to 26, genetic factors accounted for most of the stability of generalized anxiety symptoms, while environmental factors explained most of the change over time. The same work suggested that worry-avoidance and somatic-distress symptoms have overlapping genetic roots but partly separate environmental influences.

Heritable traits that sit between temperament and psychophysiology have also been studied. Anxiety sensitivity, the fear of arousal-related bodily sensations, showed a broad heritability estimate of about 45% in a twin sample, which suggests a route by which panic vulnerability could be passed down. Molecular genetic work has so far identified only small-effect variants, and no single gene accounts for a substantial portion of risk. The same is true for genetic studies more broadly, where effects are distributed across many variants and epigenetic factors may modulate them.

Temperament and cognitive biases

Behavioral inhibition, a temperament that appears in infancy and early childhood, is among the best-studied predictors. Behaviorally inhibited children are wary of novelty, withdraw from unfamiliar people and situations, and show heightened arousal to them. In a longitudinal study of 261 children aged 5–8, inhibited children were far more likely than controls to develop anxiety problems over three years. Meta-analytic work estimates that 15–20% of children have an extreme inhibited temperament, and that a substantial share of them go on to develop social anxiety disorder, though many do not, which indicates that temperament is a risk rather than a destiny. Inhibition appears to predict social anxiety most specifically, while its association with other anxiety disorders is broader.

Cognitive factors add another layer. Individuals prone to anxiety tend to interpret ambiguous stimuli as threatening, overestimate the probability and cost of harm, and underestimate their own capacity to cope. Intolerance of uncertainty is particularly relevant to generalized anxiety disorder, because it can turn ambiguous situations into occasions for worry. Such biases are often viewed as both a vulnerability and a maintaining factor, since avoidance of feared situations prevents the correction of mistaken expectations.

Environmental risks

Environmental influences are substantial and often interact with inherited temperament. Adverse life events, insecure attachment, negative parenting, and parental anxiety all appear in longitudinal models as vulnerability factors, and an overly controlling caregiving style has been linked to social anxiety in adolescents who were inhibited in early childhood. Childhood maltreatment, including physical, sexual, and emotional abuse, is associated with higher rates of anxiety disorders across the lifespan. Poverty, neighborhood violence, and chronic family stress are also linked to elevated risk, though these associations are harder to separate from genetic and family effects in observational data. Family history of anxiety increases risk for offspring through both shared genes and shared environments, which is why family studies alone cannot distinguish the two.

Neurobiological models

Neurobiological accounts centre on fear and threat circuits. The amygdala and connected regions, including the bed nucleus of the stria terminalis and parts of the prefrontal cortex, are involved in detecting threat, generating fear responses, and regulating them. Overactive threat detection combined with weaker top-down regulation is a common theme in models of anxiety, although imaging findings vary across studies and disorders. The locus coeruleus and noradrenergic systems drive arousal, and their dysregulation is thought to contribute to panic symptoms.

Neurotransmitter models emphasize serotonin and GABA. Serotonergic systems influence threat processing and mood, and the clinical effectiveness of selective serotonin reuptake inhibitors supports their relevance, although that effectiveness does not by itself prove a deficiency mechanism. GABA, the main inhibitory neurotransmitter, acts at GABA-A receptors, which benzodiazepines modulate; reduced inhibitory tone has been proposed as a mechanism, but evidence is indirect. These models are best understood as hypotheses that remain under active investigation, not as settled explanations.

Medical and substance-related contributors

Several substances can produce or intensify anxiety symptoms. Caffeine blocks adenosine receptors and stimulates arousal, and in people with panic disorder or social anxiety disorder it can provoke symptoms at relatively modest doses. Caffeine-induced anxiety disorder is recognized in DSM-5 as a substance-induced condition, and caffeine withdrawal can produce irritability, fatigue, and some anxiety-like symptoms. Alcohol affects GABA and glutamate systems, and while acute intoxication may reduce anxiety temporarily, withdrawal commonly produces restlessness, insomnia, and anxiety, sometimes in severe form. Cannabis use has been linked to new-onset panic in some longitudinal studies, with one adolescent cohort reporting higher odds of panic attacks and panic disorder among those with cannabis dependence, and cannabis withdrawal can also include anxiety and irritability. Several other drugs, including stimulants, some sedatives, and withdrawal from benzodiazepines, can similarly generate anxiety.

Medical conditions must also be considered. Thyroid disorders, cardiac arrhythmias, and other endocrine or metabolic conditions can mimic or drive anxiety symptoms, which is why medical causes are excluded in routine assessment. The causal direction between anxiety and substance use is often bidirectional: people with anxiety may use substances to relieve symptoms, and substance use may in turn produce or sustain anxiety.

Diagnosis and Assessment

No laboratory test or biomarker confirms an anxiety disorder. Diagnosis rests on a clinical interview in which the clinician reconstructs the history of the worry or fear, its onset and course, its triggers, the avoidance it produces, and the functional losses it causes. The first step is usually a full history and physical examination, followed by a check for medical or substance causes and then confirmation against DSM-5-TR criteria. Standardized questionnaires support this process but do not replace it.

Structured questionnaires and their limits

The GAD-7 is the most widely used self-report screen. It has seven items, each rated for the past two weeks, and produces a total score from 0 to 21. In its original validation against a structured diagnostic interview, a cutoff of 10 gave a sensitivity of 89% and a specificity of 82% for generalized anxiety disorder. Later studies have not reproduced these figures consistently. In one outpatient sample, the cutoff of 10 detected cases well but produced many false positives, with specificity near 45%. Systematic reviews in people with epilepsy and in patients with cancer or migraine have recommended different cutoffs, and some general-population analyses favor a threshold of about 8 or 9. The scale was built around GAD, so its results for panic disorder, social anxiety, or PTSD are only moderately reliable. A positive screen therefore prompts a diagnostic interview, but it does not establish a diagnosis or a specific disorder.

Excluding substance-induced and medical causes

DSM criteria require that the symptoms not be attributable to the physiological effects of a substance, a medication, or another medical condition. The first differential question is therefore whether the presentation is a symptom of something else. Hyperthyroidism and pheochromocytoma can produce tachycardia, tremor, sweating, and heat intolerance that closely resemble anxiety. Cardiac arrhythmias, mitral valve prolapse, asthma, and chronic obstructive pulmonary disease can generate similar sensations of breathlessness or palpitation. Common routine tests include thyroid function tests, a complete blood count, a metabolic panel, urinalysis, a urine drug screen, and an electrocardiogram, with further tests ordered when clinical suspicion is high. On the substance side, heavy caffeine intake, nicotine withdrawal, stimulant medication, alcohol, cannabis, and withdrawal from certain drugs can all cause anxiety states. Clinicians are expected to judge how much a medical or substance factor actually contributes, rather than treating any overlap as an automatic exclusion. The same logic applies to other mental disorders: panic disorder, social anxiety, obsessive-compulsive disorder, and PTSD each produce worry that can mimic generalized anxiety and must be distinguished from it.

Comorbidity, impairment, and suicide risk

Routine evaluation records the severity of impairment in work, schooling, relationships, and daily routines, and it screens for coexisting conditions. Many patients meet criteria for more than one anxiety disorder, and generalized anxiety frequently coexists with depression and substance use disorders. Suicide risk is part of the standard assessment, and clinicians may use structured instruments such as the Columbia Suicide Severity Rating Scale. Because the presence of comorbidity changes both the diagnosis and the treatment plan, an assessment that stops at the first matching disorder is considered incomplete.

Children, older adults, and people with different cultural or linguistic backgrounds

The DSM-5-TR criteria for generalized anxiety disorder require fewer associated symptoms in children than in adults, and younger patients may not describe internal states in words, which makes reliance on parents, teachers, and direct observation important. The GAD-7 has been studied in adolescents, but its cutoffs were derived mainly from adult samples.

In older adults, anxiety is often under-detected. Older people tend to under-report anxiety symptoms, and their worries more often focus on health than on finances or future events. Symptoms overlap with cognitive impairment, chronic medical illness, and sleep problems, and most instruments lack age-appropriate norms and clear cutoff scores for this group.

Cultural and linguistic factors also shape how anxiety is expressed and recognized. Some older African American adults, for example, are more likely to describe irritability, social isolation, or loneliness than to report feeling anxious or depressed, which can lead a symptom-based algorithm to misclassify them. Clinicians surveyed in one study reported that culture affects how patients express anxiety, and that Western, criteria-driven approaches may miss this. Translated questionnaires also vary in accuracy, and cutoffs validated in one language or population may not transfer directly to another, so cultural adaptation and validation are needed before results are interpreted.

Treatment and Management

Psychological treatments

Cognitive behavioral therapy (CBT) has the largest evidence base among psychological treatments for anxiety disorders. A 2018 meta-analysis of 41 randomized placebo-controlled trials, covering 2,843 patients with several anxiety-related diagnoses, found a moderate benefit over placebo, and its authors judged that more effective treatments were especially needed for PTSD, social anxiety disorder and panic disorder. Interventions built mainly on exposure produced larger effects than those relying on cognitive techniques or on combined cognitive and behavioral techniques, although the difference was not statistically significant. Exposure involves repeated, structured contact with feared situations, bodily sensations or thoughts, and it is central to the treatment of phobias and agoraphobia.

Long-term data are more encouraging for some diagnoses than others. A 2020 meta-analysis of 69 randomized trials (4,118 patients) found that CBT outperformed control conditions up to 12 months after treatment ended. At follow-up of 12 months or more, benefits remained for generalized anxiety disorder, social anxiety disorder and PTSD, but not for panic disorder. Placebo-controlled trials published after 2017, however, have reported smaller effect sizes than earlier syntheses, which suggests that expectations of CBT's benefit should be tempered.

Pharmacotherapy

SSRIs and SNRIs are the usual first-line medications. The World Federation of Societies of Biological Psychiatry (WFSBP) guidance favors an SSRI or SNRI when medication is preferred, whereas British Association for Psychopharmacology (BAP) guidance names SSRIs first and SNRIs or pregabalin as alternatives. Pregabalin is placed second-line in the WFSBP guidance because of its potential for misuse. Benzodiazepines are recommended only when SSRIs or SNRIs are not tolerated, because they are no more effective than antidepressants for these disorders and carry risks of dependence, and abrupt discontinuation can provoke withdrawal. Tricyclic antidepressants are used mainly as third- or fourth-line agents because of anticholinergic and antiadrenergic side effects and the danger of toxicity in overdose. Beta blockers such as propranolol are used mainly for somatic symptoms in specific situations, such as performance anxiety. Nonselective agents can worsen airway obstruction in people with asthma or COPD.

Antidepressants require patience and careful initiation. Clinicians generally start at a low dose and titrate, because agitation and akathisia can appear early and patients with anxiety disorders may be especially sensitive to them. Benefit often takes several weeks to emerge, and a trial of at least 8 to 12 weeks is typically needed before a drug is judged ineffective. Guidance also recognizes that a lack of any response within the first four weeks predicts failure for many first-line drugs. Maintenance matters as well: continuing antidepressants for at least six to 12 months is recommended to reduce relapse, and stopping before one year has been associated with symptom return in up to half of patients.

Adverse effects, nonresponse and augmentation

Side effects are a major reason treatment fails. Nausea, dizziness, headache, jitteriness, and sleep and gastrointestinal disturbances are common early in SSRI treatment, and they can be mistaken for worsening anxiety. Discontinuation syndrome, drug interactions through the P450 enzyme system, and a warning about suicidal thoughts in young people also need to be discussed. Observational data suggest that between 40% and 60% of patients stop antidepressants within three months.

A substantial share of patients still do not respond adequately. Before a patient is labeled treatment-resistant, clinicians are advised to confirm the diagnosis, check adherence, make sure the dose was adequate, and look for interacting drugs, comorbid depression, or substance use. Treatment-resistant generalized anxiety disorder is commonly defined as non-response to at least one antidepressant given at an adequate dose for an adequate duration. Augmentation strategies, including pregabalin and adjunctive atypical antipsychotics, have been studied in such patients, but the evidence is limited and small in scale. Combined psychotherapy and medication is used in practice, although guidance differs on whether the two should be started together, and many clinicians offer either option alone according to patient preference.

Adjunctive measures and choice of treatment

Lifestyle measures, psychoeducation and relaxation techniques are generally used alongside formal treatment rather than in place of it. Regular physical exercise and yoga have been studied as complementary approaches, and psychoeducation helps patients interpret early side effects and understand the expected time course of treatment.

The choice of treatment depends on age, severity, comorbidity and personal circumstances. Pharmacotherapy is usually considered for moderate-to-severe or functionally impairing symptoms, for inadequate response to psychotherapy, or when psychotherapy is not feasible. In children and adolescents, SSRIs have the strongest evidence among drug options, and CBT is strongly recommended. Where depression coexists, SSRIs and SNRIs can address both conditions. CBT is generally preferred during pregnancy to limit medication exposure. Previous response to a treatment, comorbid conditions and patient preference all shape decisions, and shared decision-making is considered important for adherence, since preferences that are respected tend to be associated with better engagement with care.

Public Health, Access, and Care Gaps

Burden and economic cost

Anxiety disorders are the largest group of mental disorders by number of people affected. The WHO reports that 359 million people had an anxiety disorder in 2021. In Global Burden of Disease terms, anxiety ranked sixth largest cause of years lived with disability (YLDs) worldwide in 2021. Economic estimates are less settled. A 2016 WHO-led analysis put the annual cost of depression and anxiety to the global economy at about US$1 trillion, and it projected that scaling up treatment would return roughly US$4 in better health and ability to work for each US$1 invested. The same modelling of 36 countries estimated more than 12 billion lost productivity days a year, costed at US$925 billion, for depression and anxiety together. Other analyses use different methods and reach very different totals; one secondary source cites a global direct-cost figure of up to US$6.5 trillion, so the scale of the economic burden depends heavily on which costs are counted.

Social costs fall largely on people who never receive care. When symptoms go untreated, they often persist into adulthood and are associated with higher risks of depression, substance use, suicide, and physical health problems.

The treatment gap

Effective treatments exist, yet access is very uneven. The WHO states that approximately 1 in 4 people with anxiety disorders receive treatment. A pooled analysis of community surveys from 21 countries in the World Mental Health (WMH) initiative, which used DSM-IV criteria, found that 27.6% of those with a 12-month anxiety disorder received any treatment, and only 9.8% received possibly adequate treatment. Of those with 12-month anxiety only 41.3% perceived a need for care. Treatment levels were lower in lower income countries.

Several barriers explain the gap. The WHO cites stigma, inadequate mental health care infrastructure and workforce shortages as limiting access. Financing is a central constraint: WHO Mental Health Atlas data indicate that most low-income and middle-income countries spend less than US$2 per year per person on the treatment and prevention of mental disorders compared with an average of more than $50 in high-income countries. Even where people do enter care, quality is uneven, as gaps in service coverage are compounded by gaps in quality of care. Low recognition also matters, since many people with symptoms never identify them as a health problem needing help.

Task-sharing and digital self-help

To widen access, the WHO and regional partners favour a task-sharing approach that expands the evidence-based care to be offered also by general health workers and community providers. The same strategy includes using digital technologies to support guided and unguided self-help and to deliver remote care.

Digital self-help has clear appeal but also clear limits. A recurring problem is keeping quality comparable once clinician guidance is removed. A 2024 randomized trial in a Peruvian university tested a fully self-administered programme based on acceptance and commitment therapy, mindfulness and behavioural activation, and it was delivered to people with mild to moderate symptoms. Of 427 participants, 85 (19.9%) completed all assessments, which shows how high attrition can weaken conclusions about real-world uptake. Digital delivery also depends on connectivity, so its reach is shaped by the digital divide.

Health systems, data and planning

Much of the planning evidence comes from modelled estimates rather than direct national surveys. WHO prevalence figures, for example, come from GBD 2021. National and regional bodies translate such data into services. The PAHO Mental Health Program works with countries in the Americas to strengthen mental health policies, services, and systems based on human rights, scientific evidence, and community-based care. In youth, the regional picture is concerning: despite children and adolescents comprising approximately 30% of the population in the Region of the Americas, their mental health needs remain largely unmet, and PAHO has responded with a course for non-specialist staff, such as primary health care workers, on early detection. Because many anxiety disorders begin in childhood or adolescence, early identification in schools and primary care is a key planning priority.

Equity

Risk and access are both socially patterned. Poverty, violence and inequality are associated with higher exposure to stressors and with weaker access to services, and both forces compound one another. The lower treatment rates in lower-income countries described above are one visible expression of this pattern. Addressing it requires attention to the social determinants of health as well as to clinical services, though the evidence on specific pathways varies by setting and is still being studied.

Open Questions and Ongoing Debates

Climate-related and other emerging forms of anxiety

Climate-related distress, often called eco-anxiety, has drawn wide clinical and public attention, but it has not been added to the major diagnostic manuals. Certainly "climate anxiety" is not currently a recognized diagnosis in the DSM, and many researchers and health professionals warn against medicalising this understandable and expected response. Supporters of recognition argue that a formal category legitimizes a real psychological struggle that deserves attention. The central difficulty is that DSM-5 anxiety requires worry that is excessive and out of proportion to the threat, yet whether climate anxiety can be deemed persistent or excessive, given the nature of climate change, is hard to judge. Without an agreed definition, measurement is also weak: there is not a validated clinical interview nor definitive existing classification for climate change anxiety, so cut-off scores for screening scales have had to be set against general markers of distress rather than against a gold-standard diagnosis.

Reconciling prevalence estimates

Prevalence figures for anxiety disorders differ widely, and much of that variation reflects method rather than biology. In a meta-regression of 87 studies across 44 countries, estimates of current prevalence ranged between 0.9% and 28.3%. Demographic and social factors explained much of this spread, while methodological factors in the final multivariate model (prevalence period, number of disorders and diagnostic instrument) explained an additional 13% of variance between studies. The same analysis put the adjusted global current prevalence at 7.3% (4.8–10.9%). The choice of instrument matters: in a scoping review, one structured questionnaire yielded a prevalence of anxiety disorder 1.61 times higher than clinical assessment, and self-report questionnaires generally produced higher estimates than administrative or medical-record data. Time frame is a further source of disagreement. A 29-nation WHO survey reported a lifetime GAD prevalence of 3.7%, a 12-month prevalence of 1.8% and a 30-day prevalence of 0.8%. Coverage is also uneven, since few studies have been conducted in developing and under-developed parts of the world and have little representation in the global literature. Reconciling these figures therefore requires standardised instruments and better data from low- and middle-income countries.

Predicting treatment response

A persistent clinical problem is that a considerable share of patients do not improve, and clinicians have few tools to anticipate who will. In social anxiety disorder, only about half of patients respond substantially to cognitive behavioral therapy (CBT), and before machine-learning studies appeared, there has been little evidence available to clinicians or patients about whether any individual patient is more or less likely to have a positive response to CBT. Models built from demographic, clinical and questionnaire data have so far been modest; one study of 157 patients were able to explain about 26% of the variance in final treatment improvements. Neuroimaging has been explored as an alternative. A small study combining brain responses with baseline severity accounted for about 40% of the variance in treatment response, but such results require replication in larger samples. A 2026 meta-analysis of AI models across anxiety disorders reported moderate predictive value for CBT treatment response. A further difficulty is that many studies test associations within the sample they were built on rather than prediction for a new patient, so the gap between statistical correlation and usable clinical prediction remains open.

Distinct conditions or shared dimensions

The categorical structure of DSM and ICD assumes that generalized anxiety, panic, social anxiety, specific phobia and the other disorders are separable entities with fixed thresholds. Clinical experience and epidemiology, however, show frequent overlap, shared temperamental roots such as negative affect, and high rates of co-occurrence with depression. Dimensional models, including transdiagnostic and hierarchical approaches that place anxiety within broader internalizing dimensions, propose that symptoms vary along continua that cut across diagnostic labels. Whether such dimensions should replace or complement the categories has practical consequences: a dimensional view may improve treatment matching across diagnoses, while categories remain useful for prognosis, reimbursement and research comparability. Evidence on this question remains mixed, and the answer may differ across age groups.

Gaps in neurobiology, long-term outcomes and low-resource settings

Neurobiological models of fear and threat circuitry, which draw on animal work and brain imaging, are well developed in outline but have not yet translated into biomarkers that guide individual care. Long-term outcomes are similarly under-studied; researchers have called for further research on illness trajectories and anxiety levels pre- and post-treatment. Finally, the effectiveness of interventions in low-resource settings is still poorly documented. Most trial evidence comes from high-income countries, and it is unclear how well CBT, pharmacotherapy and digital or task-shared programmes transfer to populations with limited specialist staff, high exposure to violence or poverty, and different cultural expressions of distress. Closing these gaps will require longitudinal cohorts, shared outcome measures, and trials conducted in diverse health systems.

References

1. Anxiety Disorderspsychiatryonline.org
2. Psychiatry.org - What are Anxiety Disorders?psychiatry.org
3. Generalized Anxiety Disorder: DSM-5 Criteria and What They Mean for Diagnosis (2026) - Doctronicdoctronic.ai
4. Generalized Anxiety Disorder (DSM-5-TR Clinical Reference)pasadenaclinicalgroup.com
5. DSM 5 Generalized Anxiety Disorder Checklistcarepatron.com
6. DSM-5 Definition of Anxiety and Diagnostic Criteria - ScienceInsightsscienceinsights.org
7. Anxiety Disorders, Obsessive-Compulsive and Related Disorders, Trauma- and Stressor-Related Disorders, and Dissociative Disorders in DSM-5psychiatryonline.org
8. Overview of Anxiety Disorders - Psychiatry - MSD Manual Professional Editionmsdmanuals.com
9. Chapter 1. Classification of Anxiety and Related Disorderspsychiatryonline.org
10. Anxiety and Related Disorders in Medical Settings - ebm.oneebm.one
11. Full article: Anxiety and DSM-5tandfonline.com
12. Adult separation anxiety disorder in DSM-5 - ScienceDirectsciencedirect.com
13. An organization‐ and category‐level comparison of diagnostic requirements for mental disorders in ICD‐11 and DSM‐5 - First - 2021 - World Psychiatry - Wiley Online Libraryonlinelibrary.wiley.com
14. Taxonomy of anxiety disorders—a comparison of ICD‑10 and ICD‑11 - PMCpmc.ncbi.nlm.nih.gov
15. Taxonomy of anxiety disorders—a comparison of ICD‑10 and ICD‑11ncbi.nlm.nih.gov
16. Full article: The history of generalized anxiety disorder as a diagnostic categorytandfonline.com
17. History of the DSMfscj.pressbooks.pub
18. pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov
19. Anxiolytics: Past, Present, and Future Agentspsychiatrist.com
20. ICD-11 and mental disorders: important changes, controversies, and future directionslink.springer.com
21. Anxiety Neurosis - an overviewsciencedirect.com
22. link.springer.comlink.springer.com
23. 5 Key DSM-5 Criteria for Generalized Anxiety Disorder Explainedint.livhospital.com
24. Gad Dsm 5 Criteria - Consensus Academic Search Engineconsensus.app
25. Generalized Anxiety Disorder - Psychiatry - Merck Manual Professional Editionmerckmanuals.com
26. The epidemiology of anxiety disorders: a review - PMC - NIHpmc.ncbi.nlm.nih.gov
27. Generalized Anxiety Disorder Affects More Than 1 in 10 U.S. Adultsmanagedhealthcareexecutive.com
28. Association of age and gender with anxiety disorders in older adults: A systematic review and meta‐analysisdoi.org
29. Gender-specific predictors of generalized anxiety disorder symptoms in older adults: Results of a large population-based study - ScienceDirectsciencedirect.com
30. Anxiety Disorders in Old Age: Psychiatric Comorbidities, Quality of Life, and Prevalence According to Age, Gender, and Country - ScienceDirectsciencedirect.com
31. The lifetime prevalence and impact of generalized anxiety disorders in an epidemiologic Italian National Survey carried out by clinicians by means of semi-structured interviewsbmcpsychiatry.biomedcentral.com
32. Generalized Anxiety Disorder DSM-5: Criteria for Diagnosismentalyc.com
33. Anxiety disorderen.wikipedia.org
34. Comorbid generalized anxiety disorder and its association with quality of life in patients with major depressive disorderncbi.nlm.nih.gov
35. Anxiety Disorders With Comorbid Substance Abusepsychiatrictimes.com
36. Prevalence and correlates of alcohol, cannabis, and tobacco use disorder in DSM-5 generalized anxiety disorder: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III - ScienceDirectsciencedirect.com
37. Panic Attacks and Panic Disorder - Psychiatry - Merck Manual Professional Editionmerckmanuals.com
38. Treatment of panic disorder using botulinum toxinimage-ppubs.uspto.gov
39. Expected Versus Unexpected Panic Attacks: A Naturalistic Prospective Study - ScienceDirectsciencedirect.com
40. Expecting the Unexpected: Predicting Panic Attacks from Mood and Twittermedrxiv.org
41. Agoraphobia - PsychDBpsychdb.com
42. Agoraphobia - Psychiatry - MSD Manual Professional Editionmsdmanuals.com
43. Agoraphobia in adults: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis - UpToDateuptodate.com
44. Agoraphobia DSM 5 Criteriacarepatron.com
45. Gender Differences in Panic Disorder: Findings From the National Comorbidity Surveypsychiatryonline.org
46. Is the Course of Panic Disorder the Same in Women and Men?psychiatryonline.org
47. Do Unexpected Panic Attacks Occur Spontaneously? - PMCpmc.ncbi.nlm.nih.gov
48. Why Do People Get Unexpected Panic Attacks? - Castle Craigcastlecraig.co.uk
49. Anxiety Disorders Among Women: A Female Lifespan Approachpsychiatryonline.org
50. Gender Differences in Associations of Glutamate Decarboxylase 1 Gene (GAD1) Variants with Panic Disorderncbi.nlm.nih.gov
51. Gender Differences in Panic Disorderpsychiatrictimes.com
52. Heritability of social anxiety-related concerns and personality characteristics: A twin studyresearchgate.net
53. Brazil - Heritability of social anxiety disorder: a systematic review of methodological designs Heritability of social anxiety disorder: a systematic review of methodological designsscielo.br
54. RESEARCH ARTICLE Genetic Risk Variants for Social Anxietygwern.net
55. The relationship between personality throughout adolescence and social anxiety disorder in young adulthood. A longitudinal twin studyjournals.plos.org
56. Employment Barriers, Skills, and Aspirations Among Unemployed Job Seekers With and Without Social Anxiety Disorderpsychiatryonline.org
57. A comparison of unemployed job-seekers with and without social anxiety - PMCpmc.ncbi.nlm.nih.gov
58. Occupational Impairment and Social Anxiety Disorder in a Sample of Primary Care Patients - PMCpmc.ncbi.nlm.nih.gov
59. Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)cdn.clinicaltrials.gov
60. Predictors of specific phobia in young women: A prospective community study - ScienceDirectsciencedirect.com
61. Specific Phobia - an overviewsciencedirect.com
62. Diagnosis of Specific Phobia - an overviewsciencedirect.com
63. Childhood generalized specific phobia as an early marker of internalizing psychopathology across the lifespan: results from the World Mental Health Surveysncbi.nlm.nih.gov
64. The cross-national epidemiology of specific phobia in the World Mental Health Surveyscambridge.org
65. Epidemiology of specific phobia subtypes: Findings from the Dresden Mental Health Studycambridge.org
66. Frequency of and sex distribution in specific phobia subtypes in a treatment-seeking samplecambridge.org
67. Anxiety Disorders in Children and Adolescentspsychiatry.uams.edu
68. DSM-5 and the Assessment of Childhood Anxiety Disordersjournals.sagepub.com
69. DSM-5 Separation Anxietycmhrc.org
70. Separation Anxiety and Selective Mutismcourses.lumenlearning.com
71. Prevalence and description of selective mutism in a school-based sample - PubMedpubmed.ncbi.nlm.nih.gov
72. Selective mutism: a population-based study: a research note - PubMedpubmed.ncbi.nlm.nih.gov
73. (PDF) Anxiety in Children with Selective Mutism: A Meta-analysisresearchgate.net
74. Frontiersfrontiersin.org
75. Diagnosing selective mutism: a critical review of measures for clinical practice and researchncbi.nlm.nih.gov
76. The Youth Anxiety Measure for DSM-5 (YAM-5): Development and First Psychometric Evidence of a New Scale for Assessing Anxiety Disorders Symptoms of Children and Adolescentsncbi.nlm.nih.gov
77. Myths About Selective Mutism - Selective Mutism Associationselectivemutism.org
78. Separation anxiety disorder across the lifespan: DSM-5 lifts age restriction on diagnosis - PubMedpubmed.ncbi.nlm.nih.gov
79. Separation anxiety disorder in the DSM-5 eraold.jpsychopathol.it
80. Anxiety and Obsessive-Compulsive Disorders in the DSM-5mentalhealth.com
81. Anxiety Disorders Among Children and Adolescentspsychiatryonline.org
82. Epidemiology of anxiety disorders: global burden and sociodemographic associationslink.springer.com
83. Mental disorderswho.int
84. The Age of Onset of Anxiety Disorders: A Meta-analysisresearchgate.net
85. Anxiety Statistics 2026: Prevalence and Treatmentpsychology.com
86. Global, regional and national burden of anxiety disorders from 1990 to 2019: results from the Global Burden of Disease Study 2019ncbi.nlm.nih.gov
87. Anxiety in America: 2026 Statistics & Trends — South Denver Therapysouthdenvertherapy.com
88. Age of onset of mental disorders: a review of recent literaturerepositori.upf.edu
89. (PDF) Age of onset of mental disorders and use of mental health services: Needs, opportunities and obstaclesresearchgate.net
90. The Age of Onset of Anxiety Disorderslink.springer.com
91. Anxiety symptoms preceding suicide: A Swedish nationwide record review - ScienceDirectsciencedirect.com
92. Anxiety Sensitivity and Intolerance of Uncertainty: Transdiagnostic Risk Factors for Anxiety as Targets to Reduce Risk of Suicidelink.springer.com
93. Anxiety and its disorders as risk factors for suicidal thoughts and behaviors: A meta-analytic review - ScienceDirectsciencedirect.com
94. World mental health today Latest datairis.who.int
95. Global Anxiety Statistics: The Most Common Mental Disorder Worldwidemhstats.org
96. Age of onset of mental disorders: a review of recent literature - PubMedpubmed.ncbi.nlm.nih.gov
97. Adult mental health disorders and their age at onsetcambridge.org
98. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studiesnature.com
99. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults - PubMedpubmed.ncbi.nlm.nih.gov
100. Heritability of anxiety sensitivity: a twin study - PubMedpubmed.ncbi.nlm.nih.gov
101. A twin study of DSM-III-R anxiety disorders - PubMedpubmed.ncbi.nlm.nih.gov
102. Heritability of generalized anxiety stability: a longitudinal twin study among young adults - PubMedpubmed.ncbi.nlm.nih.gov
103. Heritability and polygenic load for comorbid anxiety and depressionnature.com
104. Behavioral Inhibition in Childhood as A Risk Factor for Development of Social Anxiety Disorder: A Longitudinal Studyncbi.nlm.nih.gov
105. Behavioral Inhibition and Risk for Developing Social Anxiety Disorder: A Meta-Analytic Study - ScienceDirectsciencedirect.com
106. pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov
107. Behavioral Inhibition and Social Anxiety Disorder as Predictors of Long-Term Outcomes of Cognitive Behavioral Therapy for Youth Anxiety Disorders - PMCpmc.ncbi.nlm.nih.gov
108. Annual Research Review: Developmental pathways linking early behavioral inhibition to later anxiety - Fox - 2023 - Journal of Child Psychology and Psychiatry - Wiley Online Libraryacamh.onlinelibrary.wiley.com
109. Childhood behavioral inhibition and attachment: Links to generalized anxiety disorder in young adulthoodncbi.nlm.nih.gov
110. Caffeine and Anxiety: How Does Your Caffeine Habit Affect Anxiety?healthline.com
111. Caffeine-induced anxiety disorderen.wikipedia.org
112. A Case of Panic Attacks Developing After 10 Years of Chronic Cannabis Use in a Patient With No Prior Psychiatric History - PMCpmc.ncbi.nlm.nih.gov
113. Clinical management of cannabis withdrawal - PMC - NIHpmc.ncbi.nlm.nih.gov
114. Anxiety disorders - Knowledge @ AMBOSSamboss.com
115. Anxiety Disorders: Diagnosis & Treatmentihs.gov
116. Generalized Anxiety Disorderaccp.com
117. A Practical Guide to Anxiety DSM-5 Criteriaoak.care
118. Meeting the Criteria: A Deep Dive into GAD DSM-5 Standardsoak.care
119. Frontiersfrontiersin.org
120. GAD-7: The 7 Items, Scoring and Cutoffs — CASRAIcasrai.org
121. Psychometric Properties of the Generalized Anxiety Disorder Scale-7 (GAD-7) in Outpatients with Anxiety and Mood Disorders - PMCpmc.ncbi.nlm.nih.gov
122. Optimal cutoff score for diagnosing generalized anxiety disorder with the Generalized Anxiety Disorder 7-item scale in people living with epilepsy: A systematic review with diagnostic test accuracy meta-analysis - ScienceDirectsciencedirect.com
123. Screening for anxiety in patients with cancer: Diagnostic accuracy of GAD-7 items considering lowered GAD-7 cut-offsncbi.nlm.nih.gov
124. Validation of the Generalized Anxiety Disorder-7 (GAD-7) and GAD-2 in patients with migrainencbi.nlm.nih.gov
125. A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7jamanetwork.com
126. GAD7 Anxiety Test Questionnairepatient.info
127. Assessment of anxiety in older adults: a review of self- ...pdfs.semanticscholar.org
128. Anxiety disorders in older adults: a comprehensive review - Wolitzky‐Taylor - 2010 - Depression and Anxiety - Wiley Online Libraryonlinelibrary.wiley.com
129. Detection of anxiety symptoms and disorders in older adults: a diagnostic accuracy systematic reviewacademic.oup.com
130. Global prevalence of anxiety symptoms and its associated factors in older adults: A systematic review and meta‐analysis - PMCpmc.ncbi.nlm.nih.gov
131. Providers’ perspectives on the impact of culture in the recognition and diagnosis of anxiety - ScienceDirectsciencedirect.com
132. Journal of Mood & Anxiety Disorders 4 (2023) 100030jmoodanxdisorders.org
133. Centering Culture in Mental Health: Differences in Diagnosis, Treatment, and Access to Care Among Older People of Color - ScienceDirectsciencedirect.com
134. Comparison of Metacognitive Therapy Versus Cognitive Behavioral Therapy for Generalized Anxiety Disorder: A Meta-Analysis of Randomized Control Trialsncbi.nlm.nih.gov
135. Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials - PubMedpubmed.ncbi.nlm.nih.gov
136. Efficacy of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Meta-Analysis of Recent Literaturelink.springer.com
137. Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Systematic Review and Meta-analysisjamanetwork.com
138. A meta-analysis of relapse rates in cognitive-behavioral therapy for anxiety disorders - ScienceDirectsciencedirect.com
139. Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis - ScienceDirectsciencedirect.com
140. Full article: Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directionstandfonline.com
141. Generalized Anxiety Disorder and Panic Disorder in Adultsaafp.org
142. Generalized Anxiety Disorder (GAD) Treatment & Management: Approach Considerations, Psychotherapy, Pharmacologic Treatmentemedicine.medscape.com
143. Generalized Anxiety Disorder: 7 Essential Treatment Rulesmedaptly.com
144. What is the recommended first-line pharmacologic and psychotherapeutic management for generalized anxiety disorder?droracle.ai
145. Anxiety: Pharmacotherapycamh.ca
146. Opinion statementlink.springer.com
147. The Pharmacologic Treatment of Anxiety Disorders: A Review of Progresspsychiatrist.com
148. Beyond Pharmacology: A Narrative Review of Alternative Therapies for Anxiety Disorders - PMCpmc.ncbi.nlm.nih.gov
149. The short-term effectiveness of antidepressants in a transdiagnostic sample and determinants of side effects and medication nonadherence: an observational studyncbi.nlm.nih.gov
150. Management of treatment-resistant generalized anxiety disorder - PMCpmc.ncbi.nlm.nih.gov
151. Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance - PMCpmc.ncbi.nlm.nih.gov
152. Full article: Treatment of anxiety disorderstandfonline.com
153. Comparative efficacy and acceptability of anxiolytic drugs for the treatment of anxiety disorders: a systematic review and network meta-analysislink.springer.com
154. Anxiety disorderstranslate.google.com
155. Anxiety disorder burden inequalities across middle- and high-income countries: 1990–2035 trends and projections - PMCpmc.ncbi.nlm.nih.gov
156. Investing in treatment for depression and anxiety leads to fourfold returnwho.int
157. (PDF) Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countriesresearchgate.net
158. Anxiety disorders affect 359 million: WHO - Becker’s Behavioral Healthbeckersbehavioralhealth.com
159. Scaling-up treatment of depression and anxiety: a global return on investment analysis - ScienceDirectsciencedirect.com
160. WHO highlights urgent need to transform mental health and mental health care - PAHO/WHOpaho.org
161. Effectiveness, Usability, and Satisfaction of a Self-Administered Digital Intervention for Reducing Depression, Anxiety, and Stress in a University Community in the Andean Region of Peru: Randomized Controlled Trialncbi.nlm.nih.gov
162. Mental Health - PAHO/WHOpaho.org
163. Inter-American Mental Health Week: PAHO and OAS join forces to disseminate information and strategies on mental health in the Region - PAHO/WHOpaho.org
164. Brief digital self-care intervention for health anxiety in a Swedish Medical University Clinic: a prospective single-group feasibility studyncbi.nlm.nih.gov
165. Let's Talk About Healthpaho.org
166. The burden of anxiety among a nationally representative US adult population - ScienceDirectsciencedirect.com
167. Climate anxiety is real. That does not make it a diagnosis - The Salata Institutesalatainstitute.harvard.edu
168. Is ‘climate anxiety’ a clinical diagnosis? Should it be? - School of Public Health - University of Queenslandpublic-health.uq.edu.au
169. Nearly 1 million Canadians suffer with climate anxiety — how one Caledon artist is subverting itthepointer.com
170. Detecting and classifying eco-anxiety: development of clinical cut-off scores for the climate change anxiety scalebmcpsychology.biomedcentral.com
171. cambridge.orgcambridge.org
172. Tools used to estimate the prevalence of generalized anxiety disorder in populations: a scoping reviewncbi.nlm.nih.gov
173. A systematic review of reviews on the prevalence of anxiety disorders in adult populationsncbi.nlm.nih.gov
174. Predicting treatment response to cognitive behavior therapy in social anxiety disorder on the basis of demographics, psychiatric history, and scales: A machine learning approachncbi.nlm.nih.gov
175. Predicting Treatment Response in Social Anxiety Disorder From Functional Magnetic Resonance Imagingjamanetwork.com
176. Artificial Intelligence for Predicting Treatment Response in Patients With Anxiety Disorders After Cognitive Behavioral Therapy: Systematic Review and Meta-Analysis - PMCpmc.ncbi.nlm.nih.gov
177. Diagnosing climate anxiety? Environmental mental health challenges - The Lancet Planetary Healththelancet.com
178. Climate Anxietypsychologytoday.com
179. Prevalence of anxiety disorders in Latin America: a systematic review and meta-analysis - ScienceDirectsciencedirect.com
180. Predicting treatment response to cognitive behavior therapy in social anxiety disorder on the basis of demographics, psychiatric history, and scales: A machine learning approach - PMCpmc.ncbi.nlm.nih.gov